Flexion Therapeutics — Technical Presentation (April 2016)
10 slides from Flexion Therapeutics's technical presentation, Apr 4, 2016
Slide 1: Phase 2b Baseline Characteristics
Phase 2b Baseline Characteristics Baseline characteristic Statistic FX006 20 mg N=102 FX006 40 mg N=104 Placebo N=100 Total N=306 Gender Male Female n (%) 40 ( 39.2) 62 ( 60.8) 53 ( 51.0) 51 ( 49.0) 39 ( 39.0) 61 ( 61.0) 132 ( 43.1) 174 ( 56.9) Age (years) Mean (SD) Median Min, Max 58.2 (8.34) 57.5
Slide 2: Phase 2b WOMAC Secondary Outcomes
Phase 2b WOMAC Secondary Outcomes WOMAC A (Pain) WOMAC C (Function) *p<0.05, 2-sided
Slide 3: Phase 3 Baseline Characteristics
Phase 3 Baseline Characteristics FX006 40 mg (N=161) Placebo (N=162) TCA 40 mg (N=161) Total (N=484) Gender Male Female n(%) 58 ( 36.0) 103 ( 64.0) 66 ( 40.7) 96 ( 59.3) 64 ( 39.8) 97 ( 60.2) 188 ( 38.8) 296 ( 61.2) Age (years) Mean (SD) 61.5 (9.52) 62.4 (8.89) 62.3 (10.08) 62.1 (9.49) BMI (kg/m2) M
Slide 4: Primary Outcome: Change in Weekly Mean of Avg. Daily Pain Intensity at Week 12
Phase 3 Primary Outcome: Change from Baseline in the Weekly Mean of Avg. Daily Pain Intensity at Week 12
Slide 5: Additional Efficacy Outcomes
Phase 3 Additional Efficacy Outcomes WOMAC A (Pain) WOMAC C (Function) Weekly Mean Avg. Daily Pain Full Analysis Set *p<0.05, 2-sided FX006 vs. placebo *p<0.05, 2-sided FX006 vs. TCA
Slide 6: Phase 2b & Phase 3 Combined Safety Summary
Phase 2b & Phase 3 Combined Safety Summary SAEs: No deaths; all SAEs assessed as ‘unrelated to study drug’ Lab assessments and vital signs were unremarkable and similar across groups TEAE [N (%)] FX006 20 mg (N=102) FX006 40 mg (N=265) Placebo (N=262) TCA (N=161) TEAEs 43 (42.2%) 135 (50.9%) 129 (49
Slide 7: LS Mean Change in KOOS QOL Over Time
LS Mean Change from Baseline (+/- SE) in KOOS QOL Over Time – Full Analysis Set and Unilateral Knee OA Unilateral Knee OA Full Analysis Set
Slide 8: Rescue Medication Usage
Rescue Medication Usage 2 Tablets (1000 mg) 1.5 Tablets. 1 Tablet | (500 mg) 0.5 Tablets| (250 mg) LS Mean Change from Baseline in Daily Rescue Acetaminophen/Paracetamol Usage 0 Tablets. (Om flexion 9D) aL 4 6 8 10 12 14 16 18 20 22 24 Weeks Post Treatment —m— FX006 40 mg (w=t6) * p<0.05 Difference
Slide 9: FX006 Consistently Achieves MCII – TCA IR Does Not
FX006 Consistently Achieves MCII – TCA IR Does Not
Slide 10: Change in Weekly Average Daily Pain Intensity: FX006 40mg vs Placebo in Studies 006 and 008
Change from Baseline in Weekly Average Daily Pain Intensity Score (0-10 NRS): Comparison of FX006 40mg and Placebo in Studies 006 (Phase 2b) and 008 (Phase 3)
Flexion Therapeutics — Technical Presentation (April 2016) on 6ix